BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net …

1 day ago · Cash Balance:$24.7 million as of September 30, 2024, down from $30.7 million as of December 31, 2023. Research and Development Expenses:$7.3 million for Q3 2024, up from …

CouponFollow Extension

$24
OFF

BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net …

1 week from now

1 day ago · Cash Balance:$24.7 million as of September 30, 2024, down from $30.7 million as of December 31, 2023. Research and Development Expenses:$7.3 million for Q3 2024, up from …

yahoo.com

$9
OFF

BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net In

1 week from now

Net Income: $9.6 million for Q3 2024, compared to a net loss of $7.9 million in Q3 2023. Net Cash Used in Operating Activities: $30.7 million for the nine months ended September 30, 2024, …

gurufocus.com

$9
OFF

BiomX Inc. Reports Q3 2024 Financial Turnaround - Markets Insider

1 week from now

1 day ago · The company reported a net income of $9.6 million for Q3 2024, a significant turnaround from a net loss of $7.9 million in the previous year, primarily influenced by the …

businessinsider.com

$50
OFF

BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net …

1 week from now

BiomX Inc (PHGE) has sufficient cash reserves to fund operations into Q4 2025, supported by a $50 million private placement financing in March 2024. Negative Points Manufacturing delays …

investing.com

$0.70
OFF

BiomX (PHGE) Earnings Date And Reports 2024 - MarketBeat

1 week from now

Nov 8, 2024 · BiomX (PHGE) Earnings Date, Estimates & Call Transcripts. BiomX posted Q2 2024 earnings on August 14, 2024, reporting an EPS of $0.70, which topped the consensus …

marketbeat.com

$9
OFF

BiomX Completes Trial Enrollment, Reports $9.6M Net Income In …

1 week from now

2 days ago · Conference Call and Webcast Details. BiomX will host a conference call and webcast on November 14, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial …

stocktitan.net

64%
OFF

BiomX Inc. (PHGE) Stock Price, Quote & News - Stock Analysis

1 week from now

Nov 8, 2024 · According to 2 analysts, the average rating for PHGE stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 2,815.64% from the latest price. ...

stockanalysis.com

$32
OFF

BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong …

1 week from now

Oct 9, 2024 · BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ... Cash Balance: $32.7 million as of June 30, 2024, compared to $30.7 million …

yahoo.com

FAQs about BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net … Coupon?

What did biomx Inc (PhGe) earn in Q2 2024?

BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ... Cash Balance: $32.7 million as of June 30, 2024, compared to $30.7 million as of June 30, 2023. Research and Development Expenses: $6.9 million for Q2 2024, up from $3.8 million in Q2 2023. ...

Is biomx Inc (PhGe) a good investment?

BiomX Inc (PHGE) successfully merged with Adaptive Phage Therapeutics and completed a $50 million financing, strengthening its financial position. The company reported positive safety and efficacy results from the Phase 1b/2a trial of BX004, showing potential in treating chronic lung infections in cystic fibrosis patients. ...

What did biomx announce in the third quarter of 2024?

In the third quarter of 2024, BiomX Inc. announced the completion of patient enrollment for the Phase 2 trial of BX211 for diabetic foot osteomyelitis (DFO) and resolved manufacturing delays for BX004 in cystic fibrosis (CF), setting the stage for upcoming trial results. ...

How much did BX 004 cost in Q3 2024?

Manufacturing delays for BX 004 have pushed the expected topline results for the phase two B study to the first half of 2026. Research and development expenses increased to $7.3 million in Q3 2024, up from $5.6 million in the same period in 2023. ...

Does biomx have a diabetic foot osteomyelitis trial?

BiomX Inc (PHGE) completed patient enrollment for the phase two trial of BX 201 for diabetic foot osteomyelitis, with topline results expected in Q1 2025. The company received additional funding from the US Defense Health Agency, bringing total non-dilutive funding for the DFO trial to $36.8 million. ...

Is there an expected FDA meeting for bx004?

: Regarding BX004, is there an expected FDA meeting, and has the timeline for the Phase 2b trial been pushed out? : We had a successful FDA meeting, and the BX004 program is on track. We expect to report results in the third quarter of 2025, with no changes to the original plan. ...